•             

Cart 0

Glioma Markers

Gliomas are one of the most aggressive and lethal solid tumors of the central nervous system. Despite the alarming numbers, the molecular pathogenetic mechanisms of gliomas are not yet fully elucidated. Nowadays, several approaches aim to understand the biology of the disease and identify promising markers, which may provide effective novel therapies.

Brain tumors comprise approximately 2% of all adult cancers but form a larger fraction within the group of childhood tumors. Gliomas account for about 80% of all malignant brain tumors and are classified according to the cell type of origin, differentiation, and malignancy grade. Gliomas show considerable variability in age of onset, grade of severity, histological features, and ability to progress, as well as to metastasize

 

Anti-ID1 Antibody
Anti-ID1 Antibody

Anti-ID1 Antibody

AMAb91757
In Stock (10+)
4 311,0 kr
Anti-CHI3L1 Antibody
Anti-CHI3L1 Antibody

Anti-CHI3L1 Antibody

AMAb91777
In Stock (10+)
4 311,0 kr
Anti-NF1 Antibody

Anti-NF1 Antibody

AMAb91745
In Stock (10+)
4 311,0 kr
Anti-WNT5A Antibody
Anti-WNT5A Antibody

Anti-WNT5A Antibody

AMAb91883
In Stock (10+)
4 311,0 kr
Anti-ADAM10 Antibody
Anti-ADAM10 Antibody

Anti-ADAM10 Antibody

AMAb91898
In Stock (10+)
4 311,0 kr
Anti-PTPRN Antibody
Anti-PTPRN Antibody

Anti-PTPRN Antibody

HPA007179
In Stock (10+)
4 570,0 kr
Anti-KDELR2 Antibody

Anti-KDELR2 Antibody

HPA016459
In Stock (10+)
4 570,0 kr
Anti-EFCAB7 Antibody
Anti-EFCAB7 Antibody

Anti-EFCAB7 Antibody

HPA029611
In Stock (10+)
4 570,0 kr
Anti-CEND1 Antibody
Anti-CEND1 Antibody

Anti-CEND1 Antibody

HPA042527
In Stock (10+)
4 570,0 kr
Anti-SOX21 Antibody

Anti-SOX21 Antibody

HPA048337
On demand
4 570,0 kr
Anti-MTHFD2 Antibody

Anti-MTHFD2 Antibody

HPA049657
In Stock (10+)
4 570,0 kr
Anti-STARD7 Antibody

Anti-STARD7 Antibody

HPA064958
In Stock (10+)
4 570,0 kr

 
Download the Glioma Markers white paper

The white paper summarizes the recent developments in glioma classification and the key molecular markers for glioma stratification. Next, it highlights the glioma proteome with a list of relevant genes with favorable and unfavorable prognostic values in glioma. It then focuses on the glioma tumor microenvironment that may provide helpful insights when developing novel therapeutic strategies.

Learning points:

  • The most common form of glioma - astrocytoma
  • Glioma classification and key molecular pathology
  • Adult and pediatric gliomas: distinctive features
  • The glioma proteome
  • The glioma tumor microenvironment
  • Immunomodulation
  • Angiogenesis
  • Glioma cancer stem cells and drug resistance
  • Chi3l1 as a modulator of stem cells' cellular states
  • References
Glioma Markers